2015 Feb 07
Optimizing Treatment With Ibrutinib in High-Risk CLL
Richard Furman, M.D., director of Weill's CLL Research Center, participates in a panel discussion about therapy for patients with chronic lymphocytic leukemia (CLL) whose tumors harbor a 17p deletion. Read more